Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmaceuticals topic
No spam. Unsubscribe anytime.
Senate adopts drug‑affordability changes, creating advisory panel and pathway to lower prices
Summary
The Senate passed House Bill 483, revising the Prescription Drug Affordability framework into an advisory Affordable Medicine Act and authorizing initial price review of high‑cost drugs; sponsors said the change aligns state policy with federal Medicare negotiations and will target the most expensive medications first.
The Virginia Senate on March 11 approved House Bill 483, a reworked prescription drug affordability measure that supporters said will bring down the cost of expensive medications for Virginia patients.
The bill replaces the previous Prescription Drug Affordability Board design with an advisory panel structure charged with reviewing medication price trends and making recommendations to state health officials. Under the adopted substitute, the panel will initially focus on drugs for which federal Medicare has already negotiated lower prices and will target a limited number of high‑cost medicines in staged reviews.
"This will bring down costs for people," the senator speaking for the bill told the floor, describing an orderly process to review and, where appropriate, pursue affordability remedies modeled on federal negotiations. The substitute preserves many details of the earlier proposals but alters governance and timing so the panel functions as an advisory and review body rather than exercising immediate price‑setting authority.
Supporters framed the measure as a two‑pronged effort to contain drug prices — pairing the panel with other efforts to regulate pharmacy benefit managers — and said the staged approach will allow Virginians to benefit from federal price negotiations while the Commonwealth stands ready to expand reviews. The bill passed on a bipartisan basis, recorded at Ayes 34, Noes 6.
What happens next: The statute takes effect as drafted and directs the advisory panel to prioritize initial reviews (first 10, then additional drugs) as referenced in the bill language. Sponsors said administrative rules and implementation steps will follow in the Health and Human Services agencies.
Votes and formal actions
- Motion: passage of House Bill 483 (Prescription Drug/Affordable Medicine Act). Tally: Ayes 34, Noes 6 — Outcome: approved.
Representative quotes
- "This will bring down costs for people right away," said the bill sponsor, describing staged price review tied to federal negotiations.
Speakers (first reference shown)
- Senator from Charlottesville (Lawmaker; bill spokesperson) — first referenced SEG 2762 - Senator from Lynchburg (Lawmaker; supportive floor remarks) — first referenced SEG 2882
Authorities and programs referenced
- Affordable Medicine Act (bill title changes in debate) - Reference to federal Medicare negotiated prices used as a prioritization signal in implementation.
Clarifying details
- Implementation: initial target list draws on drugs already subject to federal negotiated prices (first 10 drugs, then additional items as statutory schedule allows). - Vote: Ayes 34, Noes 6.
Provenance
- topicintro: SEG 2762 - topfinish: SEG 2934
